
Tofacitinib curbs interferon signaling in Down syndrome phase 2 trial
Key Takeaways
- Tofacitinib met its primary safety end point in adolescents and adults with Down syndrome and immune-mediated skin disease, with a safety profile similar to that in the general population.
- Treatment lowered interferon and cytokine scores and improved hidradenitis suppurativa and alopecia areata, but without a placebo arm, efficacy findings remain exploratory.
In a phase 2 trial, tofacitinib met its safety end point and lowered interferon and cytokine scores in adolescents and adults with Down syndrome.
A JAK1/3 inhibitor already used for autoimmune disease safely reduced markers of chronic immune activation in adolescents and adults with Down syndrome, according to phase 2 results published in Cell Reports Medicine.¹,² The open-label, single-arm study met its primary safety end point, with tofacitinib showing a safety profile similar to that seen in the general population, and treatment was associated with improvements in hidradenitis suppurativa and alopecia areata.²
“We have demonstrated that we can reduce excessive immune activity and improve certain inflammatory conditions,” said senior author Joaquín Espinosa, PhD, executive director of the Linda Crnic Institute for Down Syndrome and professor of pharmacology at the University of Colorado Anschutz.¹
Tofacitinib phase 2 trial design and outcomes in Down syndrome
The trial (NCT04246372) enrolled adolescents and adults with Down syndrome and immune-mediated skin conditions, most prominently hidradenitis suppurativa and alopecia areata.¹,² Participants received oral tofacitinib twice daily for 16 weeks, with an optional extension to 40 weeks, under extensive safety monitoring.¹,² Investigators assessed skin pathology with standardized clinical scores and dermatology quality-of-life measures, alongside blood-based multi-omics analyses, neuropsychological testing, and biomarkers related to brain health and Alzheimer disease.¹ The news release did not report enrollment, dosing in milligrams, P values, or effect sizes.¹
Treatment decreased interferon scores, cytokine scores, and inflammation-associated metabolites, including the neurotoxic metabolite quinolinic acid, without overt immune suppression.¹,² Multi-omics analyses indicated that tofacitinib modulated specific inflammatory pathways, and several abnormal markers shifted toward levels seen in people without Down syndrome.¹,² First author Angela Rachubinski, PhD, of the Crnic Institute, said the drug appears to calm an overactive immune system “without weakening normal immune defenses.”¹
Participants also performed better on selected tests of attention, memory, and vocabulary, and some participants and caregivers reported favorable changes in well-being.¹
Interferon hyperactivity and immune dysregulation in Down syndrome
Trisomy 21 occurs in approximately 1 in 700 live births.³ Chromosome 21 carries genes encoding interferon receptors, and earlier Crnic Institute work linked the extra copy to chronically elevated interferon signaling and widespread immune dysregulation.¹ People with Down syndrome have high rates of autoimmunity and severe complications from infections, and immune remodeling and hypercytokinemia are present from an early age, before autoimmune diagnoses or autoantibody production.³ The current trial tested whether dampening that upstream signaling is a viable treatment strategy.¹
JAK inhibition in Down syndrome: prior clinical evidence
Tofacitinib blocks JAK1 and JAK3, kinases downstream of interferon and other cytokine receptors, and is not approved specifically for Down syndrome.¹,² An interim analysis of the first 10 participants to complete 16 weeks of treatment, published in eLife in 2024, found no serious adverse events and reported reduced skin pathology in alopecia areata, psoriasis, and atopic dermatitis.³ The new report extends that work to the full cohort and longer treatment durations.²
Limitations and next steps for JAK inhibitors in Down syndrome
Because the trial had no placebo arm, the authors characterize the efficacy findings as exploratory.² That limitation weighs most heavily on the neuropsychological results, which could reflect practice effects or other factors rather than a drug effect.¹
“The neuropsychological results are intriguing, but they are not yet proof that this medicine improves cognition,” said coauthor Lina Patel, PsyD, professor of psychiatry at CU Anschutz.¹ Known JAK inhibitor risks remain, and larger studies are needed to establish long-term safety.¹ The authors call for randomized, placebo-controlled trials to evaluate clinical benefit, optimal participant selection, and longer-term safety.¹
The team has launched a second trial in Down syndrome regression disorder, a condition involving sudden loss of neurological function linked to brain inflammation, with results expected in 2027.¹ In a separate prospective observational cohort of 126 individuals with Down syndrome regression disorder who partially responded to intravenous immunoglobulin, JAK inhibitors as second-line therapy were associated with symptomatic improvement, although B-cell depletion was associated with greater improvement and fewer adverse events.⁴
References
1. University of Colorado Anschutz Medical Campus. New treatment strategy for Down syndrome shows promise in phase 2 clinical trial. News release. PR Newswire. November 18, 2026. Accessed November 19, 2026. https://www.prnewswire.com/news-releases/new-treatment-strategy-for-down-syndrome-shows-promise-in-phase-2-clinical-trial-302944200.html
2. Rachubinski AL, Gurnee E, Wallace EB, et al. A phase 2, open-label, single-arm clinical trial of the safety and efficacy of the JAK1/3 inhibitor tofacitinib in Down syndrome. Cell Rep Med. 2026;7(11):103138. doi:10.1016/j.xcrm.2026.103138
3. Rachubinski AL, Wallace E, Gurnee E, et al. JAK inhibition decreases the autoimmune burden in Down syndrome. eLife. 2024;13:RP99323. doi:10.7554/eLife.99323
4. Santoro JD, Kazerooni L, Lucas MC, et al. Immunosuppression in Down syndrome regression disorder: a prospective observational cohort study. Brain Commun. 2026;8(3):fcag203. doi:10.1093/braincomms/fcag203
Related to this article








